Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study  by Rubio-Terrés, C. et al.
Cost of bacteraemia caused by methicillin-resistant vs. methicillin-
susceptible Staphylococcus aureus in Spain: a retrospective cohort study
C. Rubio-Terre´s1, J. Garau2, S. Grau3 and L. Martinez-Martinez4 on behalf of the Cast of Resistance Study group
1) Health Value—Health Economics and Research of Outcomes, Madrid, 2) Hospital Mu´tua de Terrasa—Infectious diseases, Terrasa, 3) Hospital del
Mar—Pharmacy, Barcelona and 4) University Hospital Marques de Valdecilla—Microbiology, Santander, Spain
Abstract
The aim of this study was to determine the impact on healthcare resource utilization and associated costs of bacteraemia due to methicil-
lin-resistant Staphylococcus aureus (MRSA) vs. methicillin-susceptible S. aureus (MSSA) strains in Spain. An observational, retrospective,
cohort multicentre study was conducted during 2005. The target population comprised Spanish patients with S. aureus bacteraemia (ﬁve
and ten cases per hospital for resistant and susceptible strains, respectively). The resources used were obtained from the hospital patient
records. The unit costs were obtained from the participating hospitals and from Spanish databases; the costs of a bacteraemic episode were
estimated from resource utilization results and expressed in euros (€). Univariate sensitivity analyses were performed. The clinical records
of 366 valid patients with S. aureus bacteraemia (121 MRSA and 245 MSSA) from 27 Spanish hospitals were reviewed. Resource use per bac-
teraemic episode was higher for MRSA cases than for MSSA cases, with longer antibiotic treatment (3.1 additional days) and greater length
of hospital stay (LOS) (2.2 additional days), more diagnostic tests, and higher rates of admission to the intensive-care unit (ICU) (7.6%). As a
consequence, a higher cost per episode was incurred, with an additional €1205 in episodes of MRSA infections (1.12-fold increase). The
main drivers of the cost difference were the higher rates of ICU admission and hospital re-admission and increased LOS. The analysis con-
ﬁrmed that there were additional costs due to resistant strains, ranging from €293 to €5188. Overall, MRSA was associated with higher
costs in bacteraemic patients, and this was attributable mainly to the greater rate of ICU admissions and increased LOS.
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Introduction
Bacterial resistance is increasing both in outpatient clinics
and in hospitals, and has become the subject of much
research. The impact of infections caused by resistant bacte-
ria is reﬂected by higher mortality, increased length of
hospital stay (LOS), and increased healthcare costs [1]. In
addition, this increased resistance reduces the therapeutic
options available for the treatment of infections involving
these microorganisms.
One of the microorganisms whose incidence has recently
increased dramatically in Spanish hospitals is methicillin-resis-
tant Staphylococcus aureus (MRSA). At present, both in Spain
and in many countries around the world, more than 25% of
S. aureus isolates are resistant to methicillin (although low
prevalences of these strains are also found in some European
regions, including The Netherlands and Scandinavian coun-
tries) [2–5].
MRSA strains are resistant to currently available b-lactam
agents and frequently also to other families of antibiotics,
with the notable exception of most of the so-called commu-
nity-acquired MRSA strains; but these strains, as compared
with sensitive strains, also cause infections, increasing the
LOS and healthcare costs [6–8].
Bacteraemia is a complex clinical syndrome that is con-
stantly changing and causes high and increasing morbidity and
mortality [9]; bacteraemias caused by MRSA are rapidly
becoming a serious problem in Spanish hospitals [10].
This study was aimed at the calculation of the impact of
MRSA vs. methicillin-susceptible S. aureus (MSSA) bactera-
emia on healthcare resources and associated costs in Spain.
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Materials and Methods
The present study was a Spanish multicentre, retrospective,
observational cohort study of the use of healthcare
resources and the associated costs in the treatment of bac-
teraemia caused by MRSA and MSSA.
The inclusion criteria were as follows: (i) either sex; (ii)
age 18 years or over; (iii) bacteraemia caused by S. aureus
(resistant or sensitive to methicillin); and (iv) strains isolated
between 1 January and 31 December 2005. Pregnant patients
and cases of bacteraemia resulting from a previous stay in
hospital were excluded.
Hospitals with an interest in the investigation from
throughout Spain were able to participate in the study. All
participating centres were required to have the study proto-
col approved by their respective ethics committees.
The microbiology department of each participating hospital
selected ﬁve MRSA and ten MSSA cases by systematic sam-
pling [11] in the following way. A skipping factor, k = n/5, was
calculated, with n being the number of MRSA bacteraemias in
the hospital during the study time period. The ﬁrst case was
selected through a random number provided in a centralized
way, and the following cases were selected by applying k
repeatedly until all MRSA bacteraemia cases were selected.
MSSA cases were selected similarly. S. aureus was identiﬁed in
every participating centre with conventional methods, usually
automated identiﬁcation–susceptibility systems [12].
To ﬁnd notable economic differences (‡ €300) in the
overall cost per patient between patients with MRSA and
those with MSSA, for a standard deviation of €600, a bilateral
a-risk of 0.05, and a b-risk of 0.10, 94 patients with MRSA
and 188 patients with MSSA were needed.
The study was performed from the perspective of the
National Health Service; therefore, only the use of health-
care resources was recorded. The costs of bacteraemia were
expressed as direct healthcare costs.
Use of resources was documented by reviewing the clini-
cal records of all the patients who met the inclusion criteria.
The following data were retrieved from the clinical history
for each episode of bacteraemia: (i) patient demographic and
clinical characteristics; (ii) antibiotic therapy; (iii) complemen-
tary tests; (iv) rates of hospitalization, admission to the
intensive-care unit (ICU), re-admission to the ward, and
LOS; (v) rates of outpatient clinics; and (vi) resources con-
sumed during the reconstitution of the vials of antibiotics
and their intravenous infusion.
The mean costs of an episode of bacteraemia caused by
resistant or sensitive strains of the microorganisms studied
were calculated. The cost of the antimicrobial treatments
was estimated by using the recommended retail price and
the rates of use per episode of bacteraemia, and taking two
possible treatments into account: (i) empirical antibiotics
(those administered before the results of the microbiological
study were known); and (ii) targeted antibiotics (those
started or continued on the day when the results of the anti-
biogram of the cultured microorganisms became available).
The costs of the other resources per episode of bacteraemia
were calculated by using their rates of use and the unit costs
obtained from the hospitals that participated in the study,
and from a database of Spanish healthcare costs in the sensi-
tivity analysis. All costs are presented in euros (€) as of
October 2006.
The cost per episode of bacteraemia was calculated on
the basis of the following tests: (i) general analysis; (ii) moni-
toring of vancomycin and/or aminoglycoside levels; (iii) diag-
nostic imaging studies; (iv) microbiological tests; and (v)
other tests, such as electrocardiogram, bronchoscopy,
laparoscopy, and lumbar puncture.
In the analysis of base-case costs, the average values of
the resources used and of the unit costs obtained from the
study were applied. The sensitivity analysis involves modifying
the values of the variables with respect to which there is
uncertainty in verifying to what extent the results of the base
case are affected.
In order to verify the robustness of this analysis, several
unifactorial simple sensitivity analyses were performed in the
following scenarios: (i) use of unit costs from a database of
healthcare costs in Spain; (ii) lower and upper limits of the
95% CI of the use of healthcare resources; (iii) minimum and
maximum values of the unit costs of the resources obtained
in the study; and (iv) minimum and maximum values of the
resources and unit costs taken together.
Qualitative and quantitative descriptive analyses were per-
formed for all variables. The qualitative variables were analy-
sed using absolute frequencies and percentages, whereas the
quantitative variables were analysed using the mean, 95% CI
for the mean, median, standard deviation, minimum, and
maximum. All demographic data and histories were analysed
to examine any difference between the groups, using the Stu-
dent t-test for independent measures in the case of continu-
ous data distributed normally, or the Mann–Whitney U-test if
the parametric requirements were not met. A chi-squared
test (or Fisher exact test, where necessary) was used to
compare the categorical variables between the treatment
groups. The Kolmogorov–Smirnov test was used to compare
the normality of the distribution of the continuous variables,
whereas the Levene test was used to analyse the homogene-
ity of the variances. All analyses were performed using the
statistical program SPSS 13.0.
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Results
Of 530 initially recruited patients, we reviewed the clinical
histories of 366 valid patients (patients from whom at least
the following data had been collected: admission date, dis-
charge date (or death), and number of complementary tests
performed) with S. aureus bacteraemia (121 MRSA and 245
MSSA); 27 hospitals from throughout Spain participated in
the study.
Older patients had more isolates of resistant strains of
S. aureus. A large percentage of MRSA strains were from
patients with nosocomial bacteraemia. No differences in
Charlson’s comorbidity index were observed among
patients with S. aureus bacteraemia, although there was a
greater incidence of cerebrovascular disease, dementia,
hemiplegia and diabetes mellitus with end-organ damage in
the group with MRSA bacteraemia, and of metastatic solid
tumours in the group with MSSA bacteraemia (Table 1).
Table 2 summarizes the results obtained with respect to
the antibiotics used in the bacteraemic episode. The propor-
tions of patients with MRSA or with MSSA infections treated
with antibiotics at the time of blood culture were 46.8% and
25.0%, respectively (p <0.001). Antimicrobial empirical ther-
apy was administered in 90.2% of patients of each type. Dif-
ferences in total duration of antibiotic therapy were not
statistically signiﬁcant.
The most frequently used (over 5%) empirical antibiotics
in patients with resistant and susceptible strains were as fol-
lows: vancomycin (16.4% and 15.7%, respectively), amoxycil-
lin–clavulanic acid (16.4% and 16.0%), ciproﬂoxacin (9.4% and
4.4%), piperacillin–tazobactam (8.2% and 5.2%), imipenem
(7.5% and 5.0%), and levoﬂoxacin (6.3% and 6.7%). The most
frequently used targeted antibiotics in MRSA and MSSA bac-
teraemia were as follows: vancomycin (26.1% and 9.7%,
respectively), teicoplanin (12.8% and 5.0%), linezolid (8.0%
and 2.4%), amoxycillin–clavulanic acid (6.6% and 9.5%), and
imipenem (5.8% and 3.7%).
As shown in Table 3, the number of complementary
tests was greater in patients with resistant microorganisms
than in the MSSA-infected patients. As compared with
the latter, patients with MRSA infection had an increased
LOS (2.2 additional days), a higher rate of admission
to the ICU (7.6% more), and a lower rate of re-admission
to hospital because of ineffective therapy (0.7% less)
(Table 3).
No differences were observed in the number of external
consultations or in the resources used for antibiotic prepara-
tion and administration. Average costs were estimated per
episode of bacteraemia. Twenty-one per cent of patients
TABLE 1. Demographic and clinical characteristics of
patients with bacteraemia included in the study
MRSA
N = 121
MSSA
N = 245 p-value
Demographic characteristics
Age (years), mean (SD) 67.9 (14.51) 62.8 (17.33) 0.003
Sex: women (%) 38.0 31.8 NS
Clinical characteristics
Community-acquired/nosocomial (%) 19.2/80.8 45.9/54.1 <0.0001
Severity: with/without sepsis/septic
shock (%)
63.6/36.4 51.0/49.0 0.023
Source of infection (%)
Central venous catheter 30.4 22.7 –
Skin and soft tissue 20.7 14.9 –
Lower respiratory tract 16.3 10.8 –
Peripheral catheter 12.0 15.5 –
Underlying condition (McCabe and Jackson)
Not life-threatening (%) 41.7 55.0 NS
Life-threatening (long-term) (%) 45.8 35.5 –
Life-threatening (short-term) (%) 12.5 9.5 –
Charlson comorbidity index, mean (SD) 3.63 (2.61) 3.24 (2.53) NS
Myocardial infarction (%) 12.4 11.4 NS
Congestive heart failure (%) 25.6 21.2 NS
Peripheral vascular disease (%) 22.3 16.7 NS
Cerebrovascular disease (%) 16.5 7.8 0.01
Dementia (%) 10.7 4.5 0.023
Chronic pulmonary disease (%) 22.3 15.1 NS
Connective tissue disease (%) 1.7 2.0 NS
Chronic ulcer (%) 5.0 6.5 NS
Liver disease (mild–moderate) (%) 2.5 4.5 NS
Diabetes mellitus (%) 21.5 18.4 NS
Hemiplegia (%) 9.1 2.9 0.009
Renal disease (moderate–severe) (%) 23.1 21.6 NS
Diabetes mellitus with end-organ
damage (%)
14.0 6.9 0.027
Malignant solid tumour (%) 14.9 14.3 NS
Leukaemia (%) 1.7 1.2 NS
Malignant lymphoma (%) 1.7 1.6 NS
Chronic liver disease (%) 8.3 6.1 NS
Metastatic solid tumour (%) 5.8 12.7 0.043
Other comorbidity factors
Intravenous drug use (%) 0.8 6.9 0.001
Use of other drugs (%) 1.7 3.7 NS
Alcoholism (%) 10.7 7.3 NS
Neutropenia (%) 1.7 1.2 NS
Immunosuppressants (%) 2.5 4.5 NS
Corticosteroids (%) 14.0 7.3 0.04
Surgery or trauma (%) 24.0 8.2 <0.05
Hepatic insufﬁciency (%) 3.3 3.3 NS
Invasive procedures (%) 23.1 22.0 NS
Mechanical ventilation (%) 9.9 4.5 0.04
Total parenteral nutrition (%) 12.4 4.5 0.006
No. of hospital admissions, mean (SD)a 2.26 (1.65) 2.00 (1.46) NS
Previous infection (%) 7.4 3.7 NS
Chemotherapy (%) 5.8 6.1 NS
Central/peripheral catheter (%) 75.2 64.9 0.04
Episode of bacteraemia
Type: primary/secondary (%) 29.8/70.2 27.5/72.5 NS
Clinical repercussion: yes/no (%) 81.8/18.2 73.0/27.0 NS
Type of sepsisb (%) – – 0.01
Sepsis 58.3 62.9 –
Severe sepsis 22.9 13.5 –
Septic shock 2.1 10.7 –
Multi-organ failure 16.7 12.9 –
Deathsc (%) 39.7 25.3 0.005
Related to the infection 61.7 56.2 NS
Related to the underlying condition 29.8 34.4 NS
Other causes 8.5 9.4 NS
SD, standard deviation; NS, non-signiﬁcant difference (p >0.05); MRSA, methicil-
lin-resistant Staphylococcus aureus ; MSSA, methicillin-susceptible S. aureus.
aDuring the previous 12 months.
bSepsis: the systematic response to infection, manifested by two or more of the
following conditions as a result of infection: (i) temperature >38C or <36C;
(ii) heart rate >90 beats/min; (iii) respiratory rate >20 breaths/min or
PaCO2 <32 mmHg; and white blood cell count >12 000/lL, <4000/lL, or >10%
immature (band) forms.
cIn-hospital mortality.
Severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypo-
tension. Hypoperfusion and perfusion abnormalities may include, but are not
limited to, lactic acidosis, oliguria, and acute mental alteration.
Septic shock: sepsis induced with hypotension despite adequate ﬂuid resuscita-
tion along with the presence of perfusion abnormalities that may include, but
are not limited to, lactic acidosis, oliguria, or acute alteration in mental status.
Patients who are receiving inotropic or vasopressor agents may not be hypoten-
sive at the time when perfusion abnormalities are measured.
Multi-organ failure: presence of altered organ function in an acutely ill patient
such that homeostasis cannot be maintained without intervention.
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were hospitalized in infectious diseases units and 36% in the
internal medicine department.
The results of the analysis of costs for the base case are
shown in Table 4. The greater consumption of resources
observed in cases of bacteraemia caused by MRSA generated
a greater cost per episode than for the MSSA cases. The
main determinants of the difference in costs were the
greater risk of admission to the ICU and the increased LOS
for patients with bacteraemia due to MRSA. The average
costs per episode of bacteraemia were €11044.59 and
€9839.25, with and without staphylococcal resistance to
methicillin, respectively (a difference of €1205.34; 1.12-fold
greater cost for MRSA episodes) (Table 4). The costs of
complementary tests were higher in cases of bacteraemia
caused by MSSA than in that caused by MRSA (Table 4), as
patients infected with MSSA received more aminoglycosides
(2.4 vs. 1.3, respectively) and underwent more laparoscopies
(1.2 vs. 0, respectively) (Table 3).
The sensitivity analyses conﬁrmed the robustness of the
base case, with incremental costs due to resistant strains
ranging from €293 to €5188 for MRSA, according to the
setting (Table 4). The use of unit costs obtained from
Spanish databases instead of the costs provided by the
participating hospitals slightly increased the cost differences
between cases caused by resistant and sensitive strains
(Table 4).
Discussion
The current study shows that MRSA bacteraemias generate
additional costs per episode, as compared with those gener-
ated by MSSA bacteraemias. The total cost of an MRSA bac-
teraemia episode was 1.12-fold higher than that of an
episode caused by sensitive strains (€11044 and €9839,
respectively), with the MRSA-associated cost increase being
mainly due to the greater rate of admissions to the ICU and
increased LOS.
The costs of S. aureus bacteraemias are higher (although
within the range) than those of Diagnosis Related Group
(DRG) 416 (septicaemia in patients aged over 17 years),
TABLE 2. Antibiotic treatment during the bacteraemic
episodes
MRSA MSSA p-value
Antibiotic treatment at the time of the blood culture
Patients treated (%) 46.8 25 <0.001
Empirical antibiotic treatmenta
Patients treated (%) 90.2 90.2 NS
Duration of treatment (days),
mean (SD)
3.45 (1.81) 3.17 (1.62) NS
Evaluation of empirical treatment (%)
Appropriateb 79 82.7 NS
Inappropriate 21 17.3 NS
Modiﬁcation or suspension of
empirical treatment (%)
61 61.1 NS
Because of antibiogram results 73.8 76.9 NS
Because of microbiological ﬁndings
not being covered
14.8 9.1 NS
Because of poor clinical
response
13.1 13.2 0.04
Because of adverse effects 6.6 0.8 NS
Because of other causes 9.8 13.2 NS
Targeted antibiotic treatmentc
Patients treated (%) 86.8 84.5 NS
Duration of treatment (days),
mean (SD)
19.07 (22.63) 16.03 (13.35) NS
No. of antibiotics, mean (SD) 2.17 (1.13) 2.00 (1.29)
Total duration of antibiotic
treatment
Days, mean (SD) 20.99 (22.03) 17.82 (13.24) NS
SD, standard deviation; NS, non-signiﬁcant statistical difference (p >0.05); MRSA,
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
aEmpirical treatment is deﬁned as that administered before the results of the
antibiogram are known.
bTreatment with an empirical antibiotic was considered to be ‘appropriate’ if at
least one of the antimicrobial agents administered showed proven in vitro activity
against the microorganism and had been administered at the correct dose and
by the correct route for a sufﬁcient period of time.
cTargeted treatment is deﬁned as that started or continued on the day when
results of the antibiogram of the cultured microorganism became available.
TABLE 3. Complementary tests, hospitalization, admission
to the intensive-care unit (ICU), and re-admissions per bac-
teraemic episode (values of the number of tests or days
expressed as mean (95% CI); patients expressed as percent-
ages)
Item MRSA MSSA
No. of complementary tests
General analyses
Biochemistry 9.5 (7.1–11.9) 7.2 (6.1–8.3)
Complete blood count 8.7 (6.5–10.9) 6.7 (5.5–7.7)
Urine sediment 2.0 (1.7–2.3) 1.9 (1.5–2.3)
Arterial blood gas 8.5 (3.4–13.6) 5.9 (4.0–7.8)
Coagulation tests 4.9 (3.7–6.1) 4.7 (3.8–5.6)
Antibiotic monitoring
Vancomycin 2.9 (1.8–4.0) 2.6 (0.3–4.9)
Aminoglycosides 1.3 (0.6–2.0) 2.4 (1.6–3.2)
Imaging tests
X-ray 4.9 (3.3–6.5) 3.8 (3.0–4.6)
Ultrasound 1.4 (1.0–1.8) 1.2 (1.1–1.3)
Computed tomography 1.5 (1.3–1.7) 1.5 (1.3–1.7)
Magnetic resonance imaging 1.2 (0.9–1.5) 1.4 (1.1–1.7)
Transoesophageal echocardiogram 1.0 (1.0–1.0) 1.4 (1.2–1.8)
Transthoracic echocardiogram 1.1 (0.9–1.3) 1.2 (1.1–1.3)
Microbiological tests
Blood cultures 3.1 (2.7–3.5) 3.0 (2.7–3.3)
Urine cultures 1.6 (1.3–1.9) 1.4 (1.3–1.5)
Other cultures 5.0 (3.7–6.3) 3.7 (2.9–4.5)
Other tests
Electrocardiogram 2.6 (1.5–3.7) 2.4 (1.9–2.9)
Bronchoscopy 1.5 (0.7–2.3) 1.0 (1.0–1.0)
Laparoscopy 0 (0–0) 1.2 (0.8–1.6)
Lumbar puncture 1.8 (0.6–3.0) 1.2 (1.0–1.4)
Hospitalization
Days in the ward 24.88 (19.9–29.9) 22.66 (18.8–26.5)
Admission to the ICU
Percentage of patients admitted 28.7 21.1
Days in the ICU 18.70 (10.9–26.5) 14.88 (10.1–19.7)
Re-admission to the ward
Percentage of patients re-admitted 5.2 5.9
Days in the warda 18.0 (15.1–20.9) 13.9 (11.8–16.1)
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
S. aureus.
aRe-admission is estimated to be 50% of the duration of the initial admission.
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which in Spain are €5710 (between €2742 and €9811). The
costs of DRG 416 are similar to data available for catheter-
related bacteraemia, according to the Spanish healthcare
database. Nevertheless, DRG 416 includes all types of sepsis,
regardless of whether the causative microorganism is resis-
tant to antimicrobials. In fact, the maximum costs of
DRG 416 are similar to those incurred for bacteraemia
caused by MSSA strains, i.e. €9839.
The costs of complementary tests were greater in cases
of bacteraemia caused by MSSA than in those caused by
MRSA, as patients infected with the sensitive strain received
more aminoglycosides. Among the latter, there were more
intravenous drug users, and the greater use of aminoglyco-
sides might be related to the presence of endocarditis.
No Spanish study evaluating the cost of bacteraemia due
to S. aureus has been identiﬁed. In 1988, a study was pub-
lished concerning the cost of catheter-related bacteraemia in
22 patients [13]; the cost was calculated to be €4152 per
episode (updated to 2006), which is lower than the cost per
MRSA bacteraemic episode (€9839).
The cost of resistance in MRSA has been evaluated in
studies carried out in other countries. One study examined
the impact of methicillin resistance on LOS and the costs in
patients with MRSA bacteraemia [14]. When deaths were
excluded, resistance to methicillin was associated with a sig-
niﬁcant increase in the mean LOS after acquisition of infec-
tion and with an increase in costs ($26 424 in the MRSA
group as compared with $19 212 in the methicillin-sensitive
group; p 0.008). Methicillin resistance was an independent
predictor of an increase in LOS (1.3-fold; p 0.016) and in
costs (1.4-fold; p 0.017). Another prospective and compara-
tive study in patients on haemodialysis and with MRSA bac-
teraemia as compared with MSSA bacteraemia also found an
increase in LOS and hospital costs [15]. A study published in
the USA in 2000 [16] calculated the mean cost of a patient
with MRSA infection to be $23 000, whereas, if the strain
was sensitive, the cost fell to $19 500. These costs were
greater than the average observed in the current study
(€11 044 and €9839, respectively). In the US study [18], the
presence of resistant strains led to a 2.7-day longer LOS
than that attributable to sensitive strains, and was associated
with higher mortality (34% vs. 24%, respectively). In our
study, LOS increased by 2.2 days, and higher mortality was
also observed (39.7% vs. 25.3%; p 0.005) in the group with
MRSA bacteraemia.
In the study of Abramson et al. [7], median attributable
hospital stay associated with MSSA bacteraemia was 4 days,
much less than the 12 days recorded for MRSA (p 0.023).
Moreover, MRSA infection led to a three-fold increase in
direct costs relative to MSSA infection. Most of the differen-
tial cost was due to the notable impact of MRSA infection
on LOS. Other recent studies have conﬁrmed that patients
with MRSA infection have increased LOS [17,18] and gener-
ate greater sanitary costs [20]. It is also interesting to point
out that Dutch/Belgian studies have shown that, from an
economic perspective, the search and destroy policy is the
best alternative for maintaining an endemic MRSA level at
<1% and is a cost-effective policy at an MRSA prevalence of
£8% [19,20].
The main limitation of our study is its retrospective
design, which explains the lack of some data in the clinical
histories in a small number of patients. This led us to carry
out the analyses only in patients with available data for each
variable. Regarding the comparability of study patients, it
must be taken into account than MRSA-infected patients
were older, with a higher incidence of nosocomial bactera-
emia. An important strength of the study was that the
results obtained were those observed in clinical practice.
Another strength was the robustness of the results of the
sensitivity analyses performed, which were based mainly on
the limits of the 95% CI of the average values obtained.
Given the high incidence of infections caused by MRSA,
quantifying their health and economic impact is important for
clinicians, hospital ﬁnancial managers, and policy-makers. Tak-
ing measures to minimize the spread of MRSA within the
hospital is essential; so this information is necessary to justify
resource allocation for the development of strategies to ﬁght
against antibiotic resistance and to prevent the spread of
TABLE 4. Cost analysis of treatment for methicillin-resis-
tant Staphylococcus aureus (MRSA) and methicillin-suscepti-
ble S. aureus (MSSA) bacteraemias; costs per bacteraemia
episode (€, October 2006)
MRSA MSSA Difference
Base casea
Empirical antibiotic 51.05 36.69 14.36
Targeted antibiotic 285.12 128.55 156.57
Complementary tests 1820.50 2572.44 )751.94
Hospitalization/ICU 8703.86 6917.51 1786.35
Consultations and intravenous
administration
184.06 184.06 0
Total 11 044.59 9839.25 1205.34
Sensitivity analysis
Unit costs as per database 12 540.80 10 775.30 1765.50
Minimum use of resources 7880.71 6189.06 1961.65
Maximum use of resources 14 518.47 15 489.20 )970.73
Maximum use of resourcesb 14 518.47 9330.34 5188.13
Minimum values of unit costs 4028.21 3426.26 601.95
Maximum values of unit costs 19 706.04 19 386.58 319.46
Minimum values of resources
and costs
3080.24 2787.24 293
Maximum values of resources
and costs
25 207.20 22 360.06 2847.14
ICU, intensive-care unit.
aBase case: mean values of the use of resources and of the unit costs obtained
from the retrospective study.
bLaparoscopy test was excluded.
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resistant organisms within the healthcare environment.
Antimicrobial management programmes should be directed
at ensuring the most appropriate use of antimicrobials rather
than focusing simply on limiting choices.
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